1,599
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and safety of plasmapheresis without plasma transfusion tandem with chemotherapy to treat multiple myeloma

, , , , , , , , , , , , ORCID Icon & show all

References

  • Costa LJ, Derman BA, Bal S, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2020;1(1):35–13.
  • Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71–84. doi:10.1038/s41571-020-0427-6
  • Rampersad C, Shaw J, Gibson IW, et al. Early antibody-mediated kidney transplant rejection associated with anti-vimentin antibodies: a case report. Am J Kidney Dis. 2020;75(1):138–143.
  • Rao A, Reddy A, Dinunno C, et al. Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: a review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors. J Oncol Pharm Pract. 2020;26(6):1533–1537.
  • Gill JC, Oakley DJ, Onwuemene OA. Strategies to aid identification of apheresis PowerFlow ports: a case report. J Emerg Nurs. 2021;47(1):21–27.
  • Goldschmidt H, Ashcroft J, Szabo Z, et al. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol. 2019;98(1):1–18.
  • Huang H, Feng Y-L, Wan T, et al. Effectiveness of sequential chemoradiation vs concurrent chemoradiation or radiation alone in adjuvant treatment after hysterectomy for cervical cancer: the STARS phase 3 randomized clinical trial. JAMA Oncol. 2021;7(3):361–369
  • Bridoux F, Arnulf B, Karlin L, et al. Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy. J Clin Oncol. 2020;38(23):2647–2657.
  • Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570–580
  • Hutchison CA, Cockwell P, Moroz V, et al. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. Lancet Haematol. 2019;6(4):e217–e228.
  • Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood J Am Soc Hematol. 2020;136(1):71–80.
  • Korttila K, Gröhn P, Gordin A, et al. Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol. 1984;24(7):273–282.
  • Marder V, Nusbacher J, Anderson F. One-year follow-up of plasma exchange therapy in 14 patients with idiopathic thrombocytopenic purpura. Transfusion. 1981;21(3):291–298.
  • Kaszuba-Zwoińska J, Gremba J, Gałdzińska-Calik B, et al. Electromagnetic field induced biological effects in humans. Przegl Lek. 2015;72(11):636–641.
  • Lemaire A, Parquet N, Galicier L, et al. Plasma exchange in the intensive care unit: technical aspects and complications. J Clin Apher. 2017;32(6):405–412.